kabutan

Oncolys BioPharma continues sharp rise as MHLW panel approves full authorization for oncolytic virus Telomelysin injection

Fri May 22, 2026 9:27 am JST Catalyst

Oncolys BioPharma Inc. <4588> extended sharp gains. Before the market open, the company announced that a Ministry of Health, Labour and Welfare subcommittee on May 21 approved the regulatory authorization of its oncolytic virus Telomelysin injection, lifting the shares. The drug is indicated for esophageal cancer patients ineligible for curative resection or chemoradiotherapy. Following official approval and the drug price listing process, the product is slated for launch during the current fiscal year as planned.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.

Related Articles